As of 2025-09-16, the Relative Valuation of Tarsus Pharmaceuticals, Inc. (TARS) is (40.86) USD. This relative valuation is based on P/E multiples. With the latest stock price at 49.36 USD, the upside of Tarsus Pharmaceuticals, Inc. based on Relative Valuation is -182.8%.
The range of the Relative Valuation is (39.49) - (41.19) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 16.2x - 18.9x | 18.8x |
| Forward P/E multiples | 18.1x - 19.7x | 18.8x |
| Fair Price | (39.49) - (41.19) | (40.86) |
| Upside | -180.0% - -183.4% | -182.8% |
| Date | P/E |
| 2025-09-12 | -22.65 |
| 2025-09-11 | -23.80 |
| 2025-09-10 | -24.93 |
| 2025-09-09 | -25.92 |
| 2025-09-08 | -26.10 |
| 2025-09-05 | -26.44 |
| 2025-09-04 | -26.35 |
| 2025-09-03 | -26.48 |
| 2025-09-02 | -26.88 |
| 2025-08-29 | -26.88 |
| 2025-08-28 | -26.69 |
| 2025-08-27 | -26.53 |
| 2025-08-26 | -27.00 |
| 2025-08-25 | -25.97 |
| 2025-08-22 | -26.27 |
| 2025-08-21 | -25.95 |
| 2025-08-20 | -25.42 |
| 2025-08-19 | -24.64 |
| 2025-08-18 | -25.06 |
| 2025-08-15 | -24.87 |
| 2025-08-14 | -24.84 |
| 2025-08-13 | -24.19 |
| 2025-08-12 | -23.57 |
| 2025-08-11 | -22.97 |
| 2025-08-08 | -21.96 |
| 2025-08-07 | -22.00 |
| 2025-08-06 | -19.11 |
| 2025-08-05 | -18.88 |
| 2025-08-04 | -19.23 |
| 2025-08-01 | -18.73 |
| 2025-07-31 | -17.81 |
| 2025-07-30 | -18.35 |
| 2025-07-29 | -18.42 |
| 2025-07-28 | -19.16 |
| 2025-07-25 | -19.04 |
| 2025-07-24 | -19.47 |
| 2025-07-23 | -19.37 |
| 2025-07-22 | -19.43 |
| 2025-07-21 | -19.35 |
| 2025-07-18 | -19.84 |
| 2025-07-17 | -19.00 |
| 2025-07-16 | -19.06 |
| 2025-07-15 | -18.62 |
| 2025-07-14 | -19.06 |
| 2025-07-11 | -17.98 |
| 2025-07-10 | -18.89 |
| 2025-07-09 | -18.95 |
| 2025-07-08 | -18.21 |
| 2025-07-07 | -18.32 |
| 2025-07-03 | -18.88 |